ABSTRACT
Completion of vaccine doses is essential for robust immunity and long-term protection against specific diseases. This study aimed to investigate factors associated with the completion of multi-dose COVID-19 vaccines (MDV) among adolescents and adults in two informal urban settlements in Nairobi, Kenya. We analyzed data from the Kenya Multisite Integrated Serosurveillance (KEMIS) project. We defined completion of MDV as receiving an additional COVID-19 vaccine dose between weeks 6 and 8 following the first COVID-19 vaccination shot. We applied the modified Poisson regression model with robust standard errors to determine the factors that were independently associated with the completion of MDV. We analyzed data from 402 individuals aged 14-90 years and found that the completion rate for MDV was 85.3%. In the adjusted analysis, participants aged ≥60 years (adjusted prevalence risk ratio [aPR] 1.30, 95% confidence interval [CI] 1.05-1.60) and those who recommended the COVID-19 vaccine to others (aPR 1.40, 95% CI 1.00-1.96) were significantly more likely to complete MDV. Individuals aged 25-59 years (aPR 1.22, 95% CI 0.99-1.50), those who perceived themselves as being at risk for COVID-19 (aPR 1.09, 95% CI 0.99-1.19), and those who had access to healthcare during the pandemic tended to have a higher completion of MDV. Overall, the MDV completion rate is relatively high, however, public health interventions should endeavor to target those being left behind such as younger individuals and those hesitant about vaccination.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://microdataportal.aphrc.org/index.php/catalog/central
Funding Statement
The study was funded by the Bill and Melinda Gates Foundation (Ref No. C1055).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the Kenya Medical Research Institute Scientific and Ethics Review Unit (Reference no. KEMRI/SERU/ CGMR-C/203/4085) and the National Commission for Science, Technology and Innovation (License no. NACOSTI/P/21/13771), gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
All the data used in this manuscript are archived at https://microdataportal.aphrc.org/index.php/catalog/central and can be formally requested for through the institutional guidelines.
